Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 3
2010 1
2011 5
2012 3
2013 5
2014 5
2015 6
2016 2
2017 5
2018 8
2019 8
2020 7
2021 6
2022 13
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Feasibility of a screening and prevention procedure for risks associated with dysphagia in older patients in geriatric units: the DYSPHAGING pilot study protocol.
Durlach O, Tripoz-Dit-Masson S, Massé-Deragon N, Subtil F, Niasse-Sy Z, Herledan C, Guittard L, Goldet K, Merazga S, Chabert M, Suel A, Dayde D, Merdinian M, Falandry C. Durlach O, et al. Among authors: falandry c. BMJ Open. 2024 Apr 19;14(4):e081333. doi: 10.1136/bmjopen-2023-081333. BMJ Open. 2024. PMID: 38642998 Free PMC article.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC. Guigay J, et al. Among authors: falandry c. Lancet Healthy Longev. 2024 Mar;5(3):e182-e193. doi: 10.1016/S2666-7568(23)00284-2. Lancet Healthy Longev. 2024. PMID: 38432247 Free article. Clinical Trial.
Tailoring a specific medical leadership development program for faculty members: the Lyon-Ottawa experience.
Falandry C, Bacchetta J, Doret-Dion M, Ferraro-Peyret C, Confavreux CB, Douplat M, Feugier P, Friggeri A, Bolze PA, Dargaud Y, Messager A, Wallon M, Geffroy L, Matillon Y, Bradwejn J. Falandry C, et al. Med Educ Online. 2024 Dec 31;29(1):2308955. doi: 10.1080/10872981.2024.2308955. Epub 2024 Jan 30. Med Educ Online. 2024. PMID: 38290044 Free PMC article.
Senotherapy, cancer, and aging.
Balducci L, Falandry C, Silvio Monfardini. Balducci L, et al. Among authors: falandry c. J Geriatr Oncol. 2023 Nov 15:101671. doi: 10.1016/j.jgo.2023.101671. Online ahead of print. J Geriatr Oncol. 2023. PMID: 37977898 Review.
Ovarian cancer in the older patient: where are we now? What to do next?
Rousseau F, Ranchon F, Bardin C, Bakrin N, Lavoué V, Bengrine-Lefevre L, Falandry C. Rousseau F, et al. Among authors: falandry c. Ther Adv Med Oncol. 2023 Sep 16;15:17588359231192397. doi: 10.1177/17588359231192397. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37724138 Free PMC article. Review.
Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO.
Herledan C, Toulemonde A, Clairet AL, Boulin M, Falandry C, Decker L, Rioufol C, Bayle A, Bertrand N. Herledan C, et al. Among authors: falandry c. Crit Rev Oncol Hematol. 2023 Oct;190:104117. doi: 10.1016/j.critrevonc.2023.104117. Epub 2023 Sep 1. Crit Rev Oncol Hematol. 2023. PMID: 37660933 Review.
85 results